Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Video-interview with Prof. Philippe Moreau about CASSIOPEIA: the first phase III study to demonstrate clinical
    benefit of daratumumab plus standard of care in transplant-eligible NDMM patients

2. Voxelotor induces robust improvements in anemia in patients with sickle cell disease

3. No evidence supporting rituximab maintenance beyond two years in patients with relapsed or refractory indolent
    non-hodgkin lymphoma

4. Fixed-duration venetoclax plus obinutuzumab: a new standard for untreated patients with chronic lymphocytic
    leukemia and coexisting comorbidities

5. Combining obinutuzumab with DHAP induces MRD negativity in three quarters of untreated mantle cell lymphoma
    patients